Skip to content

Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma

Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03237221
Enrollment
76
Registered
2017-08-02
Start date
2015-03-01
Completion date
2020-10-23
Last updated
2020-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Responsiveness, Asthma, Chest Syndrome, Clinical Anxiety, Clinical Depression, Eosinophilia, Induced Sputum, Lung Function, Nitric Oxide, Quality of Life

Brief summary

Asthma, abbreviation for bronchial asthma, is one of the common chronic airways disease that threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually occurring at night or early morning. However, there are still some patients with only persistent clinical manifestations of chest tightness. Concerned about this group of patients, we presented a subgroup of bronchial asthma, namely, chest tightness variant asthma (CTVA). This asthma subgroup usually lacks asthma-specific clinical features such as wheezing, shortness of breath, wheezing, and therefore often misdiagnosed for a long time. In order to further understand the clinical characteristics, pathogenesis, and prognosis of patients with CTVA, we conducted a national multicenter observation study to further understand CTVA. Finally, we plan to clarify whether CTVA is a relatively independent asthma phenotype. Meanwhile, reducing misdiagnosis and perform an appropriate treatment of CTVA.

Interventions

DRUGTreat patient according to Global Initiative for Asthma (GINA) guideline

Treat patient according to Global Initiative for Asthma (GINA) guideline

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. all subjects agreed to participate, understand the project, observe the use of drugs, agree to follow-up, and signed informed consent; 2. the age of more than 14 and less 80 years old, gender and ethnicity are not limited; 3. the duration time was more than 6 months,and chest tightness was the only complaint, without breathing, short of breath, chronic cough; 4. no wheezing; 5. a diagnosis of asthma supported by one or more other characteristics: * bronchial provocation test positive; * improvement in forced expiratory volume at one second (FEV1) of more than 12% and 200 mL after inhaled salbutamol; * variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week. 6. bronchodilator and glucocorticoid treatment is effective; 7. exclude the following diseases by the corresponding doctors: coronary heart disease, myocarditis, heart failure, GERD, neuromuscular disease, and mental disease.

Exclusion criteria

1. can not cooperate with related inspection or for other reasons; 2. patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and accompanied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease, neuromuscular disease, etc); 3. history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study; 4. taking part in other drug clinical trial project, or drop out less than 3 months; 5. during pregnancy, lactation women; 6. obvious abnormal of High Resolution CT.

Design outcomes

Primary

MeasureTime frameDescription
Asthma control questionnaire (ACQ)Change from Baseline ACQ score at 36 monthsAsthma control questionnaire (ACQ)

Secondary

MeasureTime frameDescription
Forced expiratory volume in one secondChange from Baseline ACQ score at 36 monthsForced expiratory volume in one second
Airway responsivenessChange from Baseline ACQ score at 36 monthsAirway responsiveness
Peak expiratory flowChange from Baseline ACQ score at 36 monthsPeak expiratory flow
Acute asthma episodeChange from Baseline ACQ score at 36 monthsAcute asthma episode
Numbers of emergency or hospitalizationChange from Baseline ACQ score at 36 monthsNumbers of emergency or hospitalization
Asthma quality of life questionnaireChange from Baseline ACQ score at 36 monthsAsthma quality of life questionnaire

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026